First Capital Ventures

B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies. We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection. We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge.

KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents. It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on Directional Genomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies Co-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007.